Premium
P4‐412: NPT001: A candidate therapeutic for clearance of beta‐amyloid and tau aggregates in Alzheimer's disease
Author(s) -
Fisher Richard,
Gan Kimberley,
Krishnan Rajaraman,
Tsubery Haim,
Masliah Eliezer,
Rockenstein Edward,
Kirschner Daniel,
Myszka David,
Wright Jason,
Solomon Beka
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.09.108
Subject(s) - chemistry , genetically modified mouse , amyloid (mycology) , thioflavin , biophysics , protein aggregation , fibril , amyloid beta , tau protein , alzheimer's disease , biochemistry , transgene , microbiology and biotechnology , pathology , biology , medicine , peptide , disease , inorganic chemistry , gene
P4-412 NPT001: A CANDIDATE THERAPEUTIC FOR CLEARANCE OF BETA-AMYLOID AND TAU AGGREGATES IN ALZHEIMER’S DISEASE Richard Fisher, Kimberley Gannon, Rajaraman Krishnan, Haim Tsubery, Eliezer Masliah, Edward Rockenstein, Daniel Kirschner, David Myszka, Jason Wright, Beka Solomon, NeuroPhage Pharmaceuticals, Cambridge, Massachusetts, United States; 2 University of California San Diego, La Jolla, California, United States; 3 Boston College, Chestnut Hill, Massachusetts, United States; 4 Biosensor Tools, Salt Lake City, Utah, United States; Tel Aviv University, Tel Aviv, Israel.